HYTN Lists on the OTC Pink Market
29 Julio 2024 - 7:00AM
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF)
“HYTN” or “the Company”, a pharmaceutical company specializing in
the development, formulation, and manufacturing of products
containing psychoactive and psychotropic compounds, including
cannabis and psilocybin, is pleased to announce its approval for
trading on the OTC PINK Market ("OTC PINK") effective July 29th,
2024, under the trading symbol “HYTNF”.
Elliot McKerr, HYTN Chief Executive Officer,
commented, “As HYTN begins trading on the OTC market, the Company
is thrilled to enhance its visibility and accessibility to a wider
range of investors. This milestone underscores HYTN's dedication to
sustained growth and value creation, aligning with the
organizations long-term strategic goals.”
The Company notes that its common shares will
continue to trade on the Canadian Securities Exchange (“CSE”) under
the symbol HYTN and the Frankfurt Stock Exchange (“FSE”) under the
symbol 85W0.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical
company that specializes in the formulation, manufacturing,
marketing, and sale of products containing psychoactive and
psychotropic compounds, including cannabis-derived cannabinoids and
psilocybe-derived tryptamines. HYTN is dedicated to becoming a
premier provider of these products across all federally regulated
markets. The Company accomplishes this by strategically identifying
market opportunities and effectively bringing innovative products
to market through its advanced development platform.
For more information contact:
Elliot McKerrChief Executive Officer1.866.590.9289
HYTN Investor Relations:1.866.590.9289investments@hytn.life
The Canadian Securities Exchange (CSE) has not
reviewed, approved, or disapproved the contents of this press
release.
Certain information contained herein may
constitute forward-looking statements that involve risks and
uncertainties. Readers are cautioned not to place undue reliance on
forward-looking statements, including but not limited to statements
regarding: (i)the Company trading on the OTC PINK market. (ii) the
Company enhancing its visibility to a wider range of investors.
(iii) the Company’s common shares continuing to trade on the CSE
and FSE. Factors that could cause actual results to vary from
forward-looking statements or may affect the operations,
performance, development, and results of the Company’s business
include, among other things: the Company’s failure to generate
sufficient cash flow from operations to meet its current and future
obligations; the Company’s failure to access sources of debt and
equity capital; changes to the regulatory framework within which
the Company operates; competitive factors, pricing pressures, and
supply and demand in the Company’s industry; and general economic
and business conditions. Any statements that are not statements of
historical fact are deemed to be forward-looking statements. The
forward-looking statements contained in this news release are made
as of the date of this news release, and, except to the extent
required by applicable law, the Company assumes no obligation to
update or revise forward-looking statements made herein or
otherwise, whether because of new information, future events, or
otherwise. The forward-looking statements contained in this news
release are expressly qualified by this cautionary note.